{"title":"Estimated Cancer Incidence in Northern Tunisia in 2023: Northern Tunisia Cancer Registry.","authors":"Houyem Khiari, Emna Arfaoui, Najet Mahjoub, Soumaya Henchiri, Alyssa Sliti, Mohamed Hsairi","doi":"10.31557/APJCP.2024.25.12.4359","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cancer is a major cause of morbidity and mortality in Tunisia. The objectives of our study were to estimate the incidence level of the main cancer sites in Northern Tunisia in 2023 and to dress projections till 2040.</p><p><strong>Methods: </strong>The population based cancer registry database of northern Tunisia was the source of cases of this study. This registry uses the active method to collect data from all health services that cover cancer patients of both public and private sectors. Incidence rate projections were established using the age-period-cohort model.</p><p><strong>Results: </strong>In 2023, according to our estimations, age standardized incidence rate (ASR) including skin cancers other than melanoma was of 165.9 /100,000 in males and 141.4/100,000 in females. In men, the five most common cancer locations (apart from the skin) were: lung with an ASR of 37.6/100,000 habitant, colorectal (29.4/100,000), bladder (24.1/100,000), prostate (15.2/100,000) and stomach (6.0/100,000). Concerning females, the top five locations (apart from the skin) were: breast (55.4/100,000), colorectal (23.0/100,000), corpus uteri (9.3/100,000), thyroid (9.0/100,000) and lung (5.8/100,000). By 2040, the incidence rates of colorectal cancer would reach more than the double in both genders. The ASR of lung and bladder cancers in males would be increasing; however, that of stomach cancer would be stable next decades. In females, while incidence rates of breast, thyroid and corpus uteri cancers would reach more than the double in 2040, cervical cancer incidence is expected to be stable next decades.</p><p><strong>Conclusion: </strong>Cancer incidence level in Northern Tunisia place the country in an intermediate level and projections seem to be worrying. Strengthening prevention, screening and early diagnosis are strongly recommended.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"25 12","pages":"4359-4369"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2024.25.12.4359","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Cancer is a major cause of morbidity and mortality in Tunisia. The objectives of our study were to estimate the incidence level of the main cancer sites in Northern Tunisia in 2023 and to dress projections till 2040.
Methods: The population based cancer registry database of northern Tunisia was the source of cases of this study. This registry uses the active method to collect data from all health services that cover cancer patients of both public and private sectors. Incidence rate projections were established using the age-period-cohort model.
Results: In 2023, according to our estimations, age standardized incidence rate (ASR) including skin cancers other than melanoma was of 165.9 /100,000 in males and 141.4/100,000 in females. In men, the five most common cancer locations (apart from the skin) were: lung with an ASR of 37.6/100,000 habitant, colorectal (29.4/100,000), bladder (24.1/100,000), prostate (15.2/100,000) and stomach (6.0/100,000). Concerning females, the top five locations (apart from the skin) were: breast (55.4/100,000), colorectal (23.0/100,000), corpus uteri (9.3/100,000), thyroid (9.0/100,000) and lung (5.8/100,000). By 2040, the incidence rates of colorectal cancer would reach more than the double in both genders. The ASR of lung and bladder cancers in males would be increasing; however, that of stomach cancer would be stable next decades. In females, while incidence rates of breast, thyroid and corpus uteri cancers would reach more than the double in 2040, cervical cancer incidence is expected to be stable next decades.
Conclusion: Cancer incidence level in Northern Tunisia place the country in an intermediate level and projections seem to be worrying. Strengthening prevention, screening and early diagnosis are strongly recommended.
期刊介绍:
Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation.
The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally.
The APJCP publishes original research results under the following categories:
-Epidemiology, detection and screening.
-Cellular research and bio-markers.
-Identification of bio-targets and agents with novel mechanisms of action.
-Optimal clinical use of existing anti-cancer agents, including combination therapies.
-Radiation and surgery.
-Palliative care.
-Patient adherence, quality of life, satisfaction.
-Health economic evaluations.